InvAscent, a private equity growth capital firm, and Morgan Stanley Private Equity Asia, a private equity investor, led a INR10bn funding round in Maiva Pharma, a company that specializes in sterile injectables. We believe that the injectables CDMO market is poised for strong growth and Maiva is well positioned to emerge as one of the leading independent players supplying to regulated markets. Under Bhaskar's leadership, Maiva has put in place building blocks for future growth with a customer-centric approach, sharp R&D focus and an emphasis on maintaining high quality standards. We are excited to be partnering with Maiva in its journey ahead,” Nirav Mehta, Morgan Stanley Private Equity Asia Managing Director and Co-Head.